Literature DB >> 25595560

Time to and risk of cardiac events after myocardial perfusion scintigraphy.

Francesco Nudi1, Giandomenico Neri2, Orazio Schillaci3, Annamaria Pinto4, Enrica Procaccini5, Maurizio Vetere2, Fabrizio Tomai6, Giacomo Frati7, Giuseppe Biondi-Zoccai8.   

Abstract

BACKGROUND: The burden of cardiovascular disease is increasing, yet it remains difficult to focus preventive strategies on populations at highest absolute and relative risks. We compared absolute and relative cardiovascular event counts, plus time to first event, among patients undergoing myocardial perfusion scintigraphy (MPS). METHODS AND
RESULTS: Our database was queried to identify subjects without myocardial necrosis or recent revascularization, focusing on cardiac death (CD) or myocardial infarction (MI). A total of 13,254 patients were included, 5436 (41%) without, and 7818 (59%) with ischemia. After 32±21 months, subjects without ischemia, compared to those with ischemia, had lower absolute (16 vs 75 events, 18% vs 82%, p<0.001) and relative (0.3% vs 1.3%, p<0.001) risk of CD. Similar findings were obtained for MI (52 vs 81 events, 39% vs 61%, p<0.001, with corresponding rates of 1.0% vs 1.4%, p<0.001, respectively). Medical therapy appeared associated with fewer outcomes in those without ischemia, with the opposite occurring for subjects with ischemia (p<0.001). Median times to event ranged between 13 and 25 months in patients without ischemia vs 2 and 14 months in those with ischemia (p<0.001 for all comparisons). Multivariable-adjusted and propensity matched analyses confirmed the independent prognostic role of myocardial ischemia and, apparently, revascularization.
CONCLUSION: Most fatal and non-fatal cardiac events appear to occur in patients with evidence of myocardial ischemia at MPS, especially those with moderate or severe ischemia not receiving revascularization during follow-up.
Copyright © 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Myocardial perfusion scintigraphy; Prognosis; Warranty period

Mesh:

Year:  2015        PMID: 25595560     DOI: 10.1016/j.jjcc.2014.11.007

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  Prognostic accuracy of myocardial perfusion imaging in octogenarians.

Authors:  Francesco Nudi; Giuseppe Biondi-Zoccai; Orazio Schillaci; Natale di Belardino; Francesco Versaci; Alessandro Nudi; Annamaria Pinto; Giandomenico Neri; Enrica Procaccini; Giacomo Frati; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2017-11-01       Impact factor: 5.952

2.  Incremental prognostic value of SPECT-MPI in chronic kidney disease: A reclassification analysis.

Authors:  Amjad M Ahmed; Waqas T Qureshi; Wesley T O'Neal; Fatima Khalid; Mouaz H Al-Mallah
Journal:  J Nucl Cardiol       Date:  2017-01-03       Impact factor: 5.952

3.  Impact of coronary revascularization vs medical therapy on ischemia among stable patients with or suspected coronary artery disease undergoing serial myocardial perfusion scintigraphy.

Authors:  Francesco Nudi; Natale Di Belardino; Francesco Versaci; Annamaria Pinto; Enrica Procaccini; Giandomenico Neri; Maurizio Vetere; Giacomo Frati; Mariangela Peruzzi; Orazio Schillaci; Achille Gaspardone; Fabrizio Tomai; Giuseppe Biondi-Zoccai
Journal:  J Nucl Cardiol       Date:  2016-05-26       Impact factor: 5.952

4.  Update of the Brazilian Guideline on Nuclear Cardiology - 2020.

Authors:  Luiz Eduardo Mastrocola; Barbara Juarez Amorim; João Vicente Vitola; Simone Cristina Soares Brandão; Gabriel Blacher Grossman; Ronaldo de Souza Leão Lima; Rafael Willain Lopes; William Azem Chalela; Lara Cristiane Terra Ferreira Carreira; José Roberto Nolasco de Araújo; Cláudio Tinoco Mesquita; José Claudio Meneghetti
Journal:  Arq Bras Cardiol       Date:  2020-02       Impact factor: 2.000

5.  A Novel Quantitative Parameter for Static Myocardial Computed Tomography: Myocardial Perfusion Ratio to the Aorta.

Authors:  Takanori Kouchi; Yuki Tanabe; Takumasa Takemoto; Kazuki Yoshida; Yuta Yamamoto; Shigehiro Miyazaki; Naoki Fukuyama; Hikaru Nishiyama; Shinji Inaba; Naoto Kawaguchi; Tomoyuki Kido; Osamu Yamaguchi; Teruhito Kido
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.